Dear customers, shareholders, and our team,
As we stand at the threshold of a new year, I wanted to take a moment to review the events of 2023 and express my gratitude for your continued support and hard work that the team has done. It has been a year of important milestones for Aiforia as the first deployments of our clinical AI-solutions were kicked-off in key markets.
It brings me great pride to announce that, with concerted effort and dedication, Aiforia has successfully met or exceeded three out of four of these predetermined targets. The 2022 changes to the regulation of in vitro diagnostic (IVD) medical devices in Europe affected the registration timeline for Aiforia's new in vitro diagnostic products. We expect to launch our first IVDR-approved AI model next year. Short-term targets for 2024–2025 will be published in January.
Pathology is undergoing a digital transformation, and the market for AI solutions for image analysis is opening up on both the preclinical and clinical sides. Looking ahead to the upcoming year, I believe we have the best team and an offering that will secure our position in an accelerating competitive environment.
Before we close the chapter of this year, I want to say thank you to our team, customers, and shareholders for the achievements of 2023. Your commitment and support have not gone unnoticed. I am excited to see what the next year brings as we continue to follow our mission to transform pathology image analysis with AI, enabling better care for each patient.
Warmest wishes for a merry and bright Holiday Season,
Best regards,
Jukka Tapaninen
CEO
Aiforia Technologies Plc